trending Market Intelligence /marketintelligence/en/news-insights/trending/rTUH3ioJwdyYU8x25mMiZQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Heron's pain drug helps patients avoid opioids after surgery in follow-up study


M&A rebound sparks optimism for near-term deal activity


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Heron's pain drug helps patients avoid opioids after surgery in follow-up study

A study combining Heron Therapeutics Inc.'s non-opioid pain medication HTX-011 with common over-the-counter painkillers helped patients avoid opioids after undergoing foot surgery.

The San Diego-based biotechnology company examined HTX-011 in combination with acetaminophen and ibuprofen, compared to HTX-011-only, bupivacaine solution and placebo in patients undergoing bunionectomy surgery. In bunionectomy, an enlargement of bone and soft tissue at the base of the big toe is removed. The study is a follow up to a phase 3 clinical trial that similarly examined the drug's success in avoiding opioid use after bunionectomy with a different group of comparative treatments.

Heron noted that 77% of the patients who received HTX-011 with over-the-counter painkillers did not require opioids to manage their postoperative pain for 72 hours. Whereas 29%, 11% and 2% of the patients in the HTX-011-only, bupivacaine solution and placebo arms did not require opioids, respectively. The patients receiving the over-the-counter combination remained opioid-free through 28 days after surgery.

The company said the results from the follow-up study support the outcomes from a previous study in which 90% of hernia repair patients were opioid-free 72 hours after the surgery and 81% did not require opioids 28 days post-surgery.

The U.S. Food and Drug Administration granted a priority review to Heron's application for HTX-011 and will make a decision on the medicine by April 30.